We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current SHNXY market cap is 1.23B. The company's latest EPS is CNY and P/E is N/A.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
| Total Revenue | 5.55B | 5.95B | 6.5B | 7.44B | 8.01B |
| Operating Income | 1.82B | 1.75B | 1.71B | 1.97B | 2.3B |
| Net Income | 299.97M | 324.86M | 348.55M | 411.19M | 496.51M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
| Total Assets | 6.44B | 7.09B | 7.33B | 8.27B | 8.29B |
| Total Liabilities | 3.33B | 3.7B | 3.68B | 3.92B | 3.51B |
| Total Equity | 3.11B | 3.39B | 3.65B | 4.35B | 4.78B |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
| Operating | 348.27M | 420.19M | 259.12M | 758.24M | 265.28M |
| Investing | -412.94M | -298.01M | -237.69M | -228.9M | -305.11M |
| Financing | -46.23M | 35.44M | -139.73M | -130.66M | -196.11M |
| Market Cap | 1.23B |
| Price to Earnings Ratio | N/A |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 0 |
| Price to Book Ratio | 0 |
| Dividend Yield | - |
| Shares Outstanding | 67.39M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0 (0%) |
| Company Name | Shandong Xinhua Pharmaceutical Company Ltd (PK) |
| Address |
no. 1 lutai avenue zibo, shandong 255086 |
| Website | https://www.xhzy.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
